Fundamental Data for ITMN

INTERMUNE(NSDQ:ITMN)

InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas, several of which are in mid-or advanced-stage human testing, known as clinical trials.

# Employees: 130

Address: 3280 Bayshore Boulevard,Brisbane,CA,USA

Phone: 415 466-2200

Fax: 415 466-2300

Website: www.intermune.com

Email: ir@intermune.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

William R. Ringo Jr. (Chmn.)

Daniel G. Welch (Presi.; C.E.O.; Dir.)

John C. Hodgman (Sr. V.P. Fin.; Administration C.F.O.)

Robin J. Steele Esq. (Sr. V.P. Legal Affairs; Genl. Counsel.; Corp. Sec.)

Howard A. Simon Esq. (Sr. V.P. Human Res. & Corp. Service; Associ. Genl.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/25/2010

Mean EPS (Next Qtr): ($0.70)

Mean EPS (Year): ($2.70)

Mean Estimate(Long Term): $15.00

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 13

Shares Performance

Period	ITMN	Compare to S&P
YTD	1.98 %	-15.60 %
4 Weeks	-16.81 %	-17.71 %
12 Weeks	-29.98 %	-33.99 %

Shares Information

Analyst Coverage: Y

Avg Volume: 599862

Shares Outstanding: 46M

Market Cap: $0.50B

52 Week High: $18.75

52 Week Low: $8.67

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 ITMN split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 76.67 %

EPS Growth in Last Year: 56.25 %

Sales Growth in Last Quarter: 244.49 %

Sales Growth in Last Quarter: 17.10 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 10.050